Thunder Gold Corp. announced promising diamond drill results from its Tower Mountain property in Ontario, revealing significant new gold mineralization beyond the current resource pit limits. All seven drill holes intersected gold grades above the resource cut-off in areas previously classified as waste, indicating potential to reduce waste and expand the resource. Notably, hole TM26-205 showed 121.5 meters averaging 0.376 g/t Au, extending mineralization 200 meters east of the pit limit. The company plans further drilling to explore this new target and update the mineral resource estimate by year-end, aiming to enhance the project's value and scale.
Thunder Gold's recent drill results highlight new gold mineralization beyond current resource limits. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 17, 2026 18:11 WIB: 26 of 31 US stocks rose today. Notable movers include EXK at USD 9.76 with a 2.41% increase and a typical hold time of 23 days, SCCO at USD 194.37 up 2.36%, and AEM at USD 199.56 rising 2.04% with 100% buy order activity.
Brinker International announced its 2026 Investor Day in Dallas, revealing plans to grow revenue by 4-6% annually and open 30 new Chili's restaurants each year by fiscal 2029. The company aims to boost net income per share with double-digit growth an...
Circle's new Arc blockchain processed 7.83 million transactions in its first 24 hours, but the intended use for USDC payments was minimal, with only about 624,000 USDC transfers recorded. The launch day was dominated by memecoin trading, causing toke...
The Bank of England kept interest rates steady at 3.75% during its September meeting, citing ongoing inflation pressures and the impact of the war in Iran on global energy markets. This decision led to a modest increase in gold prices, with spot gold...
Oracle reported a strong quarter with revenue growth of nearly 30% and a surge in cloud infrastructure revenue, yet its shares fell due to concerns over high capital expenditures and increased debt. Despite the selloff, Wall Street analysts remain bu...
The FDA has approved an updated label for IBTROZI (taletrectinib), a treatment for ROS1-positive non-small cell lung cancer (NSCLC), reflecting a median duration of response of nearly 50 months in TKI-naïve patients from the TRUST-I study. This updat...
